Functional requirements for phenotypic correction of murine β-thalassemia: Implications for human gene therapy

Blood

Volumn 97, Issue 10, 2001, Pages 3275-3282

  Persons, Derek A ^a,b   Allay, Esther R ^a,b   Sabatino, Denise E ^a,b   Kelly, Patrick ^a,b   Bodine, David M ^a,b   Nienhuis, Arthur W ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DNA VECTOR; ERYTHROCYTE STRUCTURE; ERYTHROPOIESIS; GENE THERAPY; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0035874519     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3275     Document Type: Article

References (57)

1. Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds. The Molecular Basis of Blood Diseases. 2nd ed. Philadelphia, PA: WB Saunders; 1994:157-205.
2. Weatherall DJ. Pathophysiology of thalassemia. Baillieres Clin Haematol. 1998;11:127-146.
3. Orkin S, Nathan D. The thalassemias. In: Orkin S, Nathan D, eds. Nathan and Oski's Hematology of Infancy and Childhood. 5th ed. Philadelphia, PA: WB Saunders; 1998:811-886.
4. Oliveri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous betathalassemia. N Engl J Med. 1994;331:574-578.
5. Coles SM, Klein HG, Holland PV. Alloimmunization in two multitransfused patient populations. Transfusion, 1981;21:462-466.
6. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990;58:50-55.
7. Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant, 1994;14:369-372.
8. Lucarelli G, Galimberti M, Potchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417-421.
9. Giardini C, Lucarelli G. Bone marrow transplantation for beta-thalassemia, Hematol Oncol Clin North Am. 1999;13:1059-1064.
10. Lucarelli G, Cliff RA, Galimberti M, et al. Bone marrow transplant in adult thalassemic patients, Blood. 1999;93:1164-1167.
11. Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation. 1997;63:854-860.
12. Williams DA, Lemischka IR, Nathan DG, Mulligan RC. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature. 1984;310:476-480.
13. Dick JE, Magli MC, Huszar D, Phillips RA, Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell. 1985;42:71-79.
14. Sorrentino BP, Nienhuis AW. The hematopoietic system as a target for gene therapy. In: Friedmann T, ed. The Development of Gene Therapy. New York, NY: Cold Spring Harbor Laboratory Press; 1999:351-426.
15. Plavec I, Papyannopoulou T, Maury C, Meyer F. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood. 1993;81:1384-1392.
16. Ren S, Wong BY, Li J, Luo XN, Wong PM, Atweh GF. Production of genetically stable high-titer retroviral vectors that carry a human gamma-globin gene under the control of the alpha-globin locus control region. Blood. 1996;87:2518-2524.
17. Raftopoulos H, Ward M, Lebouche P, Bank A. Long-term transfer and expression of the human beta-globin gene in a mouse transplant model. Blood. 1997;90:3414-3422.
18. Emery DW, Morrish F, Li Q, Stamatoyannopoulos G. Analysis of gamma-globin expression cassettes in retrovirus vectors. Hum Gene Ther. 1999;10:877-888.
19. Persons DA, Nienhuis AW. Gene therapy for the hemoglobin disorders: past, present and future. Proc Natl Acad Sci U S A. 2000;97:5022-5024.
20. Kalberer CP, Pawlluk R, Imren S, et al. Preselection of retrovirally transduced bone marrow avoids stem cell gene silencing and age-dependent extinction of expression of human b-globin in engrafted mice. Proc Natl Acad Sci U S A. 2000;97:5411-5415.
21. Sabatino DE, Seidel NE, Aviles-Mendoza GJ, et al. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter. Proc Natl Acad Sci U S A. 2000;97:13294-13299.
22. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406:82-86.
23. Wu T, Kim HJ, Sellers SE, et, al. Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther. 2000;1:285-293.
24. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human longterm repopulating hematopoietic stem cells. Nat Med. 2000;6:652-658.
25. Wagemaker G, Visser TP, van Bekkum DW. Cure of murine thalassemia by bone marrow transplantation without eradication of endogenous stem cells. Transplantation. 1986;42:248-251.
26. van den Bos C, Kieboom D, Wagemaker G. Correction of murine beta-thalassemia by partial bone marrow chimerism: selective advantage of normal erythropoiesis. Bone Marrow Transplant. 1993;12:9-13.
27. Bethel CA, Murugesh D, Harrison MR, Mohandas N, Rubin EM. Selective erythroid replacement in murine beta-thalassemia using fetal hematopoietic stem cells. Proc Natl Acad Sci U S A. 1993;90:10120-10124.
28. Barker JE, Compton ST. Hematopoietic repopulation of adult mice with beta-thalassemia. Blood. 1994;83:828-832.
29. van den Bos C, Kieboom D, van der Sluijs JP, Baert MR, Ploemacher RE, Wagemaker G. Selective advantage of normal erythrocyte production after bone marrow transplantation of alpha-thalassemic mice. Exp Hematol. 1994;22:441-446.
30. Nesci S, Manna M, Andreani M, Fattorini P, Graziosi G, Lucarelli G. Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant. 1992;10:143-146.
31. Kapelushnik J, Or R, Filon D, et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood. 1995;86:3241-3246.
32. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 1996;87:3494-3499.
33. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25:401-404.
34. Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. Cell. 1983;34:1043-1052.
35. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies, O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A. 1995;92:11608-11612.
36. Ciavatta DJ, Ryan TM, Farmer SC, Townes TM. A mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc Natl Acad Sci U S A. 1995;92:9259-9263.
37. Sabatino D E, Cline AP, Gallagher PG, et al. Substitution of the human beta-spectrin promoter for the human agamma-globin promoter prevents silencing of a linked human beta-globin gene in transgenic mice. Mol Cell Biol. 1998;18:6634-6640.
38. Sabatino DE, Wong C, Cline AP, et al. A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice. J Biol Chem. 2000;275:28549-28554.
39. Gaensler KM, Kitamura M, Kan W. Germ-line transmission and developmental regulation of a 150-kb yeast artificial chromosome containing the human beta-globin locus in transgenic mice. Proc Natl Acad Sci U S A. 1993;90:11381-11385.
40. Whitney JB. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem Genet. 1978;16:667-672.
41. Weaver S, Haigwood NL, Hutchinson III CA, Edgell MH. DNA fragments of the Mus musculus beta globin haplotypes Hbbs and Hbbd. Proc Natl Acad Sci U S A. 1979;76:1385-1389.
42. Mardiney M, Malech HL. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood. 1996;87:4049-4056.
43. Thorpe SJ, Thein SL, Sampietro M, Craig JE, Mahon B, Huehns ER. Immunochemical estimation of haemoglobin types in red blood cells by FACS analysis. Br J Haematol. 1994;87:125-132.
44. Bean TL, Ney PA. Multiple regions of p45 NF-E2 are required for beta-globin gene expression in erythroid cells. Nucleic Acids Res. 1997;25:2509-2515.
45. Sorrentino B, Ney P, Bodine D, Nienhius AW. A 46 base pair enhancer sequence within the locus activating region is required for induced expression of the gamma-globin gene during erythroid differentiation. Nucleic Acids Res. 1990;18:2721-2731.
46. Morley BJ, Abbott CA, Wood WG. Regulation of human fetal and adult globin genes in mouse erythroleukemia cells. Blood. 1991;78:1355-1363.
47. Stamatoyannopoulos G, Nienhuis AW. Hemoglobin switching. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds. The Molecular Basis of Blood Diseases. 2nd ed. Philadelphia, PA: WB Saunders; 1994:107-155.
48. Popp RA, Popp DM, Johnson FM, Skow LC, Lewis SE, Hematology of a murine beta-thalassemia: a longitudinal study. Ann N Y Acad Sci. 1985;445:432-444.
49. Thein SL, Wainscoat JS, Sampietro M, et al. Association of thalassemia intermedia with a betaglobin gene haplotype. Br J Haematol. 1987;65:367-373.
50. Fessas P. Thalassemia clinical and patho-physiological considerations. Trans R Soc Trop Med Hyg. 1967;61:164-173.
51. Richard RE, Wood B, Zeng H, Jin L, Papayannopoulou T, Blau CA, Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood. 2000;95:430-436.
52. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136-1143.
53. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O(6)-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther. 20013:78-87.
54. Davis BM, Koc ON, Gerson SL. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood. 2000;95:3078-3084.
55. Persons DA, Sawai N, Allay ER, Nienhuis AW, Sorrentino BP. Treatment of murine beta-thalassemia using in vivo selection of normal bone marrow cells expressing the P140K MGMT gene [abstract]. Blood. 2000;96:591a.
56. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol. 2000;27:78-81.
57. Carella AM, Champlin R, Salvin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350.